Laquinimod Increases BDNF Serum Levels for Neurological Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as Parkinson's disease, Huntington's disease, and others are limited by low brain-derived neurotrophic factor (BDNF) levels, which are not effectively addressed by existing therapies.
Innovation Solution
Laquinimod, a novel synthetic compound with high oral bioavailability, is administered periodically to increase BDNF serum levels in humans, either alone or in combination with other BDNF-increasing agents, for treating various BDNF-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for neurological disorders, then treatment is provided, but BDNF levels remain low and are not effectively addressed
Solution Approach 1:
The patent changes the chemical parameter by introducing laquinimod, a novel synthetic compound with a specific chemical structure (N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide). This compound specifically targets and increases BDNF levels, resolving the contradiction by changing the chemical composition parameter of the treatment to achieve both therapeutic effectiveness and elevated BDNF levels
Solution Approach 2:
Laquinimod acts as an intermediary substance that mediates between the administration route and the target BDNF levels. The compound serves as a carrier mechanism to achieve the desired biological effect, bridging the gap between existing therapy limitations and the need for increased BDNF
2Reliability
If laquinimod is administered to increase BDNF levels, then therapeutic benefits are achieved, but the complexity of treatment regimen increases
Solution Approach 1:
Laquinimod is designed with multi-functionality, serving both as an immunomodulator (for multiple sclerosis treatment) and as a BDNF-elevating agent (for neurological disorders). This universal compound addresses multiple therapeutic needs simultaneously, reducing overall treatment complexity while maintaining therapeutic benefits
Solution Approach 2:
The patent specifies periodic administration of laquinimod (e.g., once daily or once weekly) rather than continuous dosing. This periodic action maintains therapeutic BDNF levels while simplifying the treatment regimen and improving patient compliance, thereby resolving the contradiction between therapeutic effectiveness and regimen complexity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Laquinimod for use in the treatment of Huntington's disease. A method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. A method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. Use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. A pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.